Sentinel lymph node biopsy and completion lymph node dissection for malignant melanoma are not standard of care

Clinics in Dermatology

Volumn 27, Issue 4, 2009, Pages 350-354

  Coldiron, Brett M ^a   Dinehart, Scott ^b   Rogers, Howard W ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c Advanced Dermatology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH; CANCER PREVENTION; CANCER RESEARCH; CANCER STAGING; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ELECTIVE SURGERY; HEALTH CARE QUALITY; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MELANOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PRIVATE HOSPITAL; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE BIOPSY; STANDARD;

HUMANS; LYMPH NODE EXCISION; MELANOMA; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 66949179059     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2009.02.006     Document Type: Review

References (44)

1. Rubenfeld G.D., McNamara-Aslin E., and Rubinson L. The pulmonary artery catheter, 1967-2007: rest in peace?. JAMA 298 (2007) 458-461
2. Handley W.S. The genesis of cancer (1931), Paul, Trench, Trubner, London 222
3. Snow H. Melanotic cancerous disease. Lancet ii (1892) 872-874
4. Balch C.M. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 6 (1988) 163-172
5. Veronesi U., Adamus J., Bandiera D.C., et al. Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 297 (1977) 627-630
6. Cascinelli N., Morabito A., Santinami M., MacKie R.M., and Belli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 351 (1998) 793-796
7. Sim F.H., Taylor W.F., Pritchard D.J., and Soule E.H. Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 61 (1986) 697-705
8. Balch C.M., Soong S.J., Bartolucci A.A., et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224 (1996) 255-263 [discussion 263-6]
9. Silberman A.W. Malignant melanoma. Practical considerations concerning prophylactic regional lymph node dissection. Ann Surg 206 (1987) 206-209
10. Slingluff Jr. C.L., Stidham K.R., Ricci W.M., Stanley W.E., and Seigler H.F. Surgical management of regional lymph nodes in patients with melanoma. Experience with 4682 patients. Ann Surg 219 (1994) 120-130
11. Morton D.L., Thompson J.F., Essner R., et al. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: a multicenter trial. Multicenter Selective Lymphadenectomy Trial Group. Ann Surg 230 (1999) 453-463 [discussion 463-5]
12. Reintgen D., Cruse C.W., Wells K., et al. The orderly progression of melanoma nodal metastases. Ann Surg 220 (1994) 759-767
13. Thompson J.F. The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol 8 9 Suppl (2001) 44S-47S
14. Gershenwald J.E., Thompson W., Mansfield P.F., et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17 (1999) 976-983
15. McMasters K.M., Sondak V.K., Lotze M.T., and Ross M.I. Recent advances in melanoma staging and therapy. Ann Surg Oncol 6 (1999) 467-475
16. Balch C.M., Buzaid A.C., Atkins M.B., et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88 (2000) 1484-1491
17. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19 (2001) 3622-3634
18. Ferrone C.R., Panageas K.S., Busam K., Brady M.S., and Coit D.G. Multivariate prognostic model for patients with thick cutaneous melanoma: importance of sentinel lymph node status. Ann Surg Oncol 9 (2002) 637-645
19. Zogakis T.G., Essner R., Wang H.J., Foshag L.J., and Morton D.L. Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol 14 (2007) 1604-1611
20. Vuylsteke R.J., van Leeuwen P.A., Statius Muller M.G., Gietema H.A., Kragt D.R., and Meijer S. Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results. J Clin Oncol 21 (2003) 1057-1065
21. Wagner J.D., Ranieri J., Evdokimow D.Z., et al. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma. Plast Reconstr Surg 112 (2003) 486-497
22. Gadd M.A., Cosimi A.B., Yu J., et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 134 (1999) 381-387
23. Thomas J.M. Prognostic false-positivity of the sentinel node in melanoma. Nat Clin Pract Oncol 5 (2008) 18-23
24. van Akkooi A.C., de Wilt J.H., Voit C., Verhoef C., Suciu S., and Eggermont A.M. Sentinel lymph-node false positivity in melanoma. Nat Clin Pract Oncol 5 (2008) E2
25. Wong S.L., Morton D.L., Thompson J.F., et al. Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol 13 (2006) 809-816
26. Morton D.L., and Cochran A.J. The case for lymphatic mapping and sentinel lymphadenectomy in the management of primary melanoma. Br J Dermatol 151 (2004) 308-319
27. Yan S., and Brennick J.B. False-positive rate of the immunoperoxidase stains for MART1/MelanA in lymph nodes. Am J Surg Pathol 28 (2004) 596-600
28. Holt J.B., Sangueza O.P., Levine E.A., et al. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am J Clin Pathol 121 (2004) 58-63
29. Starz H., Haas C.J., Schulz G.M., and Balda B.R. Tyrosinase RT-PCR as a supplement to histology for detecting melanoma and nevus cells in paraffin sections of sentinel lymph nodes. Mod Pathol 16 (2003) 920-929
30. Biddle D.A., Evans H.L., Kemp B.L., et al. Intraparenchymal nevus cell aggregates in lymph nodes: a possible diagnostic pitfall with malignant melanoma and carcinoma. Am J Surg Pathol 27 (2003) 673-681
31. Davids V., Kidson S.H., and Hanekom G.S. Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate. Mol Pathol 56 (2003) 43-51
32. Morton D.L., Thompson J.F., Cochran A.J., et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355 (2006) 1307-1317
33. van Akkooi A.C., Bouwhuis M.G., de Wilt J.H., Kliffen M., Schmitz P.I., and Eggermont A.M. Multivariable analysis comparing outcome after sentinel node biopsy or therapeutic lymph node dissection in patients with melanoma. Br J Surg 94 (2007) 1293-1299
34. Tanis P.J., Nieweg O.E., van den Brekel M.W., and Balm A.J. Dilemma of clinically node-negative head and neck melanoma: outcome of "watch and wait" policy, elective lymph node dissection, and sentinel node biopsy-A systematic review. Head Neck 30 (2008) 380-389
35. Koskivuo I., Talve L., Vihinen P., Mäki M., Vahlberg T., and Suominen E. Sentinel lymph node biopsy in cutaneous melanoma: a case-control study. Ann Surg Oncol 14 (2007) 3566-3574
36. Gutzmer R., Al Ghazal M., Geerlings H., and Kapp A. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients. Br J Dermatol 153 (2005) 1137-1141
37. González U. Cloud over sentinel node biopsy: unlikely survival benefit in melanoma. Arch Dermatol 143 (2007) 775-776
38. Sondak V.K., Zager J.S., Messina J.L., and Thomas J.M. Sentinel lymph node biopsy as the standard of care for cutaneous melanoma. Clin Adv Hematol Oncol 5 (2007) 483-490
39. Kretschmer L., and Hilgers R. Research supports the view that sentinel node biopsy is the standard of care in high-risk primary melanoma. J Clin Oncol 24 (2006) 2965-2966
40. Henderson M.A. Completion lymphadenectomy for melanoma patients with a positive sentinel node biopsy remains standard of care. Ann Surg Oncol 13 (2006) 761-763
41. National Comprehensive Cancer Network. Melanoma guides. Available at. http://www.nccn.org
42. Cohen M.H. Complementary and integrative medical therapies, the FDA, and the NIH: definitions and regulation. Dermatol Ther 16 (2003) 77-84
43. Tsai K.Y. Systemic adjuvant therapy for patients with high-risk melanoma. Arch Dermatol 143 (2007) 779-782
44. Stephanie G., Benedetti J., and Crowley J. Clinical trials in oncology. 2nd ed. (2003), CRC Press, Boca Raton (FL)